What is the mechanism of action of Cyclophosphamide in cancer treatment?

What is the mechanism of action of Cyclophosphamide in cancer treatment?

• A. Inhibition of DNA synthesis
• B. Activation by liver enzymes
• C. Direct DNA intercalation
• D. Reducing blood supply to tumors

Answer: (B)

The mechanism of action of Cyclophosphamide involves its activation by liver enzymes, making this choice the correct explanation of how the drug functions in cancer treatment. Cyclophosphamide is a prodrug, meaning it requires conversion within the body to become active. This conversion primarily occurs in the liver through the action of cytochrome P450 enzymes. Once activated, Cyclophosphamide forms DNA cross-links, which interfere with DNA replication and ultimately lead to cell death, particularly in rapidly dividing cancer cells. The other options do not accurately describe the mechanism of Cyclophosphamide. While inhibition of DNA synthesis is a consequence of its action, it is not the direct mechanism by which Cyclophosphamide operates; it is the result of the metabolites produced after activation. Similarly, direct DNA intercalation is associated with other classes of chemotherapy agents and is not relevant to Cyclophosphamide’s action. The option regarding reducing blood supply to tumors pertains more to anti-angiogenic therapies rather than the specific action of Cyclophosphamide. Thus, recognizing the importance of liver enzyme activation is key to understanding how Cyclophosphamide exerts its therapeutic effects in cancer treatment.

The mechanism of action of Cyclophosphamide involves its activation by liver enzymes, making this choice the correct explanation of how the drug functions in cancer treatment. Cyclophosphamide is a prodrug, meaning it requires conversion within the body to become active. This conversion primarily occurs in the liver through the action of cytochrome P450 enzymes. Once activated, Cyclophosphamide forms DNA cross-links, which interfere with DNA replication and ultimately lead to cell death, particularly in rapidly dividing cancer cells.

The other options do not accurately describe the mechanism of Cyclophosphamide. While inhibition of DNA synthesis is a consequence of its action, it is not the direct mechanism by which Cyclophosphamide operates; it is the result of the metabolites produced after activation. Similarly, direct DNA intercalation is associated with other classes of chemotherapy agents and is not relevant to Cyclophosphamide’s action. The option regarding reducing blood supply to tumors pertains more to anti-angiogenic therapies rather than the specific action of Cyclophosphamide. Thus, recognizing the importance of liver enzyme activation is key to understanding how Cyclophosphamide exerts its therapeutic effects in cancer treatment.